Non-linear Dose Response of Lymphocyte Cell Lines to Microtubule Inhibitors

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Microtubule (MT) inhibitors are vital anti-cancer drugs, but their precise concentration-dependent effects on neoplastic cells remain unclear.
• While high doses typically induce mitotic arrest and cell death, subtle effects of lower doses on cell physiology and death mechanisms are increasingly recognized.
• Reducing MT inhibitor doses could mitigate side effects, but requires understanding low-dose efficacy and mechanisms.

Purpose of the Study:

• To investigate the differential effects of MT inhibitors (paclitaxel, nocodazole, vinorelbine) on cell cycle progression and cell death in human lymphoid B-cell lines across a wide concentration range.
• To identify specific concentration thresholds ('trigger' concentrations) that induce distinct cellular responses.
• To analyze the heterogeneity and viability of cell populations accumulating in the sub-G1 phase after low-dose treatment.

Main Methods:

• Treatment of human lymphoid B-cell lines with paclitaxel, nocodazole, and vinorelbine at various concentrations.
• Assessment of cell cycle distribution using flow cytometry to detect G2/M and sub-G1 phase accumulation.
• Multi-label analysis of live cells to evaluate the heterogeneity and viability of the sub-G1 population.

Main Results:

• All tested MT inhibitors exhibited similar dose-dependent effects, with a defined 'trigger' concentration causing G2/M phase arrest.
• Concentrations just below the 'trigger' threshold led to accumulation in the sub-G1 phase.
• The sub-G1 population was heterogeneous, containing viable cells even after 24 hours of exposure, indicating complex cell death pathways.
• Similar effects were observed in cells expressing Tat-protein.

Conclusions:

• High and low concentrations of MT inhibitors differentially impact cell cycle progression and induce distinct cell death pathways.
• The concentration of MT inhibitors is critical in determining the cellular response, affecting cell cycle arrest and the nature of cell death.
• Low-dose MT inhibitor treatment may induce complex cellular responses, including a heterogeneous sub-G1 population with potentially viable cells, warranting further investigation into their therapeutic potential and mechanisms.